CD274 and neoplasm: A comparable trend is evident in triple SCMs, where combinations of tumour & immune isPLA+/−, tumour PLA−, and tumour & immune PLA+ are more frequent in PD patients compared to CR, suggesting an increased level of PD-1/PD-L1 interactions in non-responsive patients (Fig. 6B, D).